Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE II STUDY COMPARING DARATUMUMAB combined with BORTEZOMIB-CYCLOPHOSPHAMIDE- DEXAMETHASONE (Dara-VCd) VERSUS THE ASSOCIATION OF BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE (VTd) AS PRE TRANSPLANT INDUCTION AND POST TRANSPLANT CONSOLIDATION, BOTH FOLLOWED BY A MAINTENANCE PHASE WITH IXAZOMIB ALONE OR IN COMBINATION WITH DARATUMUMAB, IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) YOUNG PATIENTS eligible for AUTOLOGOUS STEM CELL TRANSPLANTATION

Trial Profile

A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE II STUDY COMPARING DARATUMUMAB combined with BORTEZOMIB-CYCLOPHOSPHAMIDE- DEXAMETHASONE (Dara-VCd) VERSUS THE ASSOCIATION OF BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE (VTd) AS PRE TRANSPLANT INDUCTION AND POST TRANSPLANT CONSOLIDATION, BOTH FOLLOWED BY A MAINTENANCE PHASE WITH IXAZOMIB ALONE OR IN COMBINATION WITH DARATUMUMAB, IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) YOUNG PATIENTS eligible for AUTOLOGOUS STEM CELL TRANSPLANTATION

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top